Search results for: 'pi3 kinase p110'
-
BA4637 IMM-H007Summary: IMM-H007 (WS070117) is an orally effective (AMP-activated protein kinase) activator and (transforming growth factor beta 1) antagonist. - BA5784 ZT-12-037-01Summary: ZT-12-037-01 is a target-selective serine/threonine kinase inhibitor that interacts with STK19 protein with high affinity and inhibits NRAS-driven malignant transformation of melanocytes.
- BA6329 BLU-945Summary: BLU-945 is a potent, highly selective, reversible epidermal growth factor receptor tyrosine kinase inhibitor (TKIs) with oral activity.
- BA3688 PF-06454589Summary: PF-06447475 is a potent, selective, blood-brain barrier permeable kinase inhibitor targeting WTLRRK and G2019S with values of 3nM and 11nM, respectively.
- BA2785 BMS-536924Summary: BMS-536924 is an orally active, competitive and selective inhibitor of insulin-like growth factor receptor kinase and insulin receptor at 100nM and 73nM, respectively.
- BA6511 VNPP433-3βSummary: VNPP433-3β is a molecular gel degrader that targets androgen receptor and its splice variants and serine/threonine protein kinases that interact with MAP kinase.
- BA3735 FPFT-2216Summary: FPFT-2216 is a "molecular glue" compound that degrades phosphodiesterase 6D, the zinc finger transcription factors Ikaros, Aiolos, and casein kinase 1α.
- BA8893 LMTK3-IN-1Summary: LMTK3-IN-1 is an ATP-competitive inhibitor of lemur tyrosine kinase 3 (LMTK3) (=2.5 μM) and acts through the ubiquitin proteasome pathway to degrade LMTK3.
- BA8990 AnsornitinibSummary: Ansornitinib is an orally active dual kinase inhibitor that inhibits platelet-derived growth factor receptor (PDGFR) and vascular endothelial growth factor receptor (VEGFR2).
- BA6334 MavelertinibSummary: Mavelertinib is a selective, orally effective and irreversible tyrosine kinase inhibitor with values of 5, 4, 12 and 3 nM for Del, L858R and double mutant T790M/L858R and T790M/Del, respectively.